Results on triple combination (A+V+O) for high risk patients -with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll

[spi3]

The Bottom Line:

In this ongoing trial, the triple combination therapy using acalabrutinib, venetoclax, and obinutuzumab is highly active. Thus far this drug combination has produced durable remissions as a frontline treatment in patients with TP53 mutation CLL and has been generally well tolerated, with a low 2.9% incidence of atrial fibrillation and zero of the more serious abnormal ventricular heart irregularities -

See report at

cllsociety.org/2023/01/ash-...

[LeoPa]

What is the out of pocket cost? $50,000 a month?

[spi3 in reply to LeoPa]

I'm not sure - my husband is in a Dana-Faber study - our health insurance pays for all scans, visit co-pays, blood tests...the study just pays for the medicine(s).

[LeoPa in reply to spi3]

Oh my, I forgot the other costs. The meds alone must be 50K a month.

[Smakwater]

Sounds encouraging spi3,

JM

[spi3 in reply to Smakwater]

it is and we get to see Dr Davis in two weeks so I can ask him about his findings. I'm so glad they have the studies and are generating more treatments - I'm hoping and praying they will eradicate CLL and all types of cancers too (in the next 5 years).....

[Smakwater]

Yes, it would be so nice to put and end to the fear and suffering.

Thank You for sharing the hope.

All the best to you on this treatment path!

[spi3 in reply to Smakwater]

Praying g the best for you too